Etoricoxib Induced Toxic Epidermal Necrolysis in a case of Systemic Lupus Erythematosus: A Case Report

Authors

  • Asim Pandey Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal
  • Samriddhi Parajuli Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal
  • Alok Dhungel Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal
  • Rahul Devkota Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal
  • Angel Dongol Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal

DOI:

https://doi.org/10.31729/jnma.7665

Keywords:

case reports; etoricoxib; systemic lupus erythematosus; toxic epidermal necrolysis.

Abstract

Toxic epidermal necrolysis is a potentially life-threatening dermatological condition whose pathogenesis and exact treatment are not yet known. Drugs like anticonvulsants, allopurinol and non-steroidal anti-inflammatory drugs like etoricoxib, a selective cyclo-oxygenase-2 inhibitor prescribed for pain management are associated with a high risk of toxic epidermal necrolysis. It is also associated with immunodeficiency and dysregulated immune reactions like systemic lupus erythematosus, an autoimmune disease in which organs and cells undergo damage initially mediated by tissue binding auto-antibodies and immune complexes. Here, a 34 year old lady was presented in emergency with multiple maculopapular rashes over the neck and trunk region after treatment with etoricoxib for osteoarthritis of the left foot.

Author Biography

Alok Dhungel, Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal

Department of Internal Medicine

Downloads

Published

2022-08-31

How to Cite

Pandey, A., Parajuli, S., Dhungel, A., Devkota, R., & Dongol, A. (2022). Etoricoxib Induced Toxic Epidermal Necrolysis in a case of Systemic Lupus Erythematosus: A Case Report. Journal of Nepal Medical Association, 60(253), 811–814. https://doi.org/10.31729/jnma.7665

Issue

Vol. 60 No. 253 (2022): JNMA: PUBLISHED MONTHLY

Section

Case Reports

License

Copyright (c) 2022 Asim Pandey, Samriddhi Parajuli, Alok Dhungel; Rahul Devkota, Angel Dongol

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.

Most read articles by the same author(s)